The Food and Drug Administration has expanded the approval of Rituxan® injection (rituximab) to include the treatment of children ≥2 years of age who have granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), in combination with glucocorticoids.
Rituximab is a CD20-directed cytolytic monoclonal antibody first approved in 1997 to treat non-Hodgkin’s lymphoma and is now approved for multiple indications in adults, including for the treatment of GPA and MPA.
Read the full press release at https://bit.ly/39tR7an.
